CD44 is a nexus between prognosis and therapeutics for brain cancer management
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.CD44 is identified as a key molecule for brain cancer prognosis and treatment. This finding supports a new prognostic index and suggests cold atmospheric plasma (CAP) as a promising therapy for brain cancers.
Area Of Science
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background
- Brain tumors, primary and metastatic, are a major cause of cancer mortality and reduced quality of life.
- Identifying key molecular drivers is crucial for improving brain cancer management.
Purpose Of The Study
- To identify a hub molecular controlling brain cancer progression.
- To establish a prognostic index and therapeutic strategy for brain cancer.
Main Methods
- Pan-cancer analysis of 9 datasets for brain metastases to identify a prognostic hub gene.
- Computational analysis of the hub gene in gliomas for diagnostic value.
- In vitro and in vivo investigation of cold atmospheric plasma (CAP) targeting the hub molecule in glioma models.
Main Results
- CD44 was identified as the central molecule for brain cancer prognosis and therapeutics, applicable to both primary and metastatic tumors.
- A CD44-dependent index for overall survival prognosis was developed.
- Cold atmospheric plasma (CAP) demonstrated potential for arresting brain cancers by targeting CD44.
Conclusions
- This study first characterizes CD44's relevance in brain cancers, integrating prognosis and therapeutics for primary and metastatic types.
- The findings may inspire novel theranostic designs for enhanced brain cancer management.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...